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Abstract
Background: Altered glutamatergic neurotransmission and neuropeptide levels play a central role in migraine
pathomechanism. Previously, we confirmed that kynurenic acid, an endogenous glutamatergic antagonist, was able
to decrease the expression of pituitary adenylate cyclase-activating polypeptide 1–38, a neuropeptide with known
migraine-inducing properties. Hence, our aim was to reveal the role of the peripheral kynurenine pathway (KP) in
episodic migraineurs. We focused on the complete tryptophan (Trp) catabolism, which comprises the serotonin and
melatonin routes in addition to kynurenine metabolites. We investigated the relationship between metabolic
alterations and clinical characteristics of migraine patients.
Methods: Female migraine patients aged between 25 and 50 years (n = 50) and healthy control subjects (n = 34)
participated in this study. Blood samples were collected from the cubital veins of subjects (during both the
interictal/ictal periods in migraineurs, n = 47/12, respectively). 12 metabolites of Trp pathway were determined by
neurochemical measurements (UHPLC-MS/MS).
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Results: Plasma concentrations of the most Trp metabolites were remarkably decreased in the interictal period of
migraineurs compared to healthy control subjects, especially in the migraine without aura (MWoA) subgroup: Trp
(p < 0.025), L-kynurenine (p < 0.001), kynurenic acid (p < 0.016), anthranilic acid (p < 0.007), picolinic acid (p < 0.03), 5-
hydroxy-indoleaceticacid (p < 0.025) and melatonin (p < 0.023). Several metabolites showed a tendency to elevate
during the ictal phase, but this was significant only in the cases of anthranilic acid, 5-hydroxy-indoleaceticacid and
melatonin in MWoA patients. In the same subgroup, higher interictal kynurenic acid levels were identified in
patients whose headache was severe and not related to their menstruation cycle. Negative linear correlation was
detected between the interictal levels of xanthurenic acid/melatonin and attack frequency. Positive associations
were found between the ictal 3-hydroxykynurenine levels and the beginning of attacks, just as between ictal
picolinic acid levels and last attack before ictal sampling.
Conclusions: Our results suggest that there is a widespread metabolic imbalance in migraineurs, which manifests
in a completely depressed peripheral Trp catabolism during the interictal period. It might act as trigger for the
migraine attack, contributing to glutamate excess induced neurotoxicity and generalised hyperexcitability. This data
can draw attention to the clinical relevance of KP in migraine.
Keywords: Episodic migraine, Interictal-ictal periods, Plasma tryptophan metabolites: kynurenine-serotonin-
melatonin pathways, Aura-without aura, Clinical features
Introduction
Migraine is one of the most frequent primary headache
disorder associated with high socioeconomic impact.
The pathomechanism is complex and several factors
control the development of attacks, among others distur-
bances of glutamatergic neurotransmission can lead to
excitotoxicity and generalised neuronal hyperexcitability,
which underlie the formation of migraine [1–3]. In this
study, we focused on the investigation of kynurenine
pathway (KP), which is closely related to the glutamater-
gic system [4], and potentially interacts with neuropep-
tides as well [5]. Therefore, kynurenine metabolites may
be relevant as biomarkers and/or therapeutic targets for
migraine.
KP is the main metabolic route (95%) of tryptophan
(Trp) in parallel with the synthesis of serotonin (5-hy-
droxytryptamine, 5-HT) and melatonin (N-acetyl-5-
methoxytrypamine, MELA). Since all three molecules
are involved in migraine-related processes [6–11], the
question arises whether metabolites of kynurenine con-
tribute to or are affected by these processes. The KP un-
folds as follows: firstly, L-kynurenine (KYN) is formed
from Trp indirectly during an oxidative step, then three
different enzymes determine the generation of further
metabolites: 1) kynurenine aminotransferases (KATs) are
able to form kynurenic acid (KYNA) from KYN, 2) the
kynurenine monooxygenase can generate 3-
hydroxykynurenine (3-HK) followed by the formation of
xanthurenic acid (XA) and 3-hydroxy-anthranilic acid
(3-HANA), and 3) the kynureninase is able to form
anthranilic acid (ANA), which can transform to 3-
HANA again that generates quinolinic acid (QUINA)
and picolinic acid (PICA) in further indirect steps.
Several metabolites are neuroactive, but they have differ-
ent sources and actions: e.g. KYNA is synthetised in as-
trocytes and behaves as a neuroprotective agent, while
QUINA is the product of activated microglial cells/mac-
rophages and it is considered a neurotoxic compound
for the central nervous system (CNS) [12] (Fig. 6).
These metabolites are present in the nano/micromolar
range in the human brain and they act partly on the glu-
tamatergic system [13, 14]. Both ionotropic and metabo-
tropic glutamate receptors are involved in mechanisms
related to migraine [15, 16], but N-methyl-D-aspartate
(NMDA) receptors have a pronounced role in the onset
of cortical spreading depression (CSD) [17, 18], the
development of hyperalgesia [19] and the activation of
migraine generators [20, 21]. Since the inhibition of
NMDA receptors is believed to protect against
glutamate-caused excitotoxicity and KYNA has a com-
petitive antagonist effect on these receptors [4], it is pos-
sible that the KP has therapeutic potential in headache
disorders. Moreover, KYNA exhibits affinity to other re-
ceptors as well (e.g. α-amino-3-hydroxy-5-methyl-4-iso-
xazole propionic acid receptors, G protein coupled
receptor 35, aryl hydrocarbon receptors, α7-nicotinic
acetylcholine receptor), enabling widespread modulating
properties [22]. Downregulated KP was observed in
different animal models of TS activation [23–26], while
administration of KYN, KYNA and certain KYNA-
derivatives seemed effective in preventing migraine-
related neuronal, molecular and electrophysiological
alterations in preclinical studies [5, 27–30].
However, human studies about the function of the KP
in headache diseases are scarce: Curto and co-workers
were the first who measured the metabolites of the KP
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in the serum of patients diagnosed with chronic mi-
graine and cluster headache [31, 32]. They demonstrated
that chronic migraine is associated with abnormalities of
the KP compared to healthy controls and emphasised
the significance of ANA. However, a systematic and de-
tailed examination, which contains the 1) determination
of not only the KP, but also main peripheral Trp metab-
olites with particular regard to the influence of 2) inter-
ictal/ictal periods and 3) clinical features of episodic
migraine patients is needed which can help us under-
stand the role of kynurenine metabolites and develop
new, potential strategies in the diagnosis and therapy of
migraine.
Our aims were:
– to determine the concentrations of main metabolites
of Trp pathway (5-HT, MELA and KP) in the
peripheral plasma of episodic migraine patients
compared to healthy control subjects.
– to distinguish between metabolic alterations in the
interictal/ictal periods and in the two subgroups of
patients (migraine with and without aura)
– to describe the relationship between altered Trp




All patients enrolled in this study are treated as outpa-
tients at the Department of Neurology, Faculty of
Medicine and University of Szeged. Investigations were
conducted after the approval of the local Ethical
Committee of the University of Szeged (87/2009) and
the Department of Health Administration of National
Public Health Centre (29022–5/2019/EÜIG, 28324–5/
2019/EÜIG) adhering to the most recent revision of the
Declaration of Helsinki.
Inclusion criteria: Episodic migraine patients (EM, n =
50) fulfilling the criteria of the 3rd edition of The Inter-
national Classification of Headache Disorders were regis-
tered, and healthy control subjects (n = 34) were
recruited. In order to keep the groups as homogenous as
possible, they were matched in terms of age and sex
(25–50 years, female).
Peripheral blood samples were collected from the cu-
bital vein of patients during the interictal (attack free)
and ictal (attack) periods, and from healthy controls on
one occasion. Ethylenediaminetetraacetic acide contain-
ing blood collection tubes (BD Vacutainer K2E 6ml)
were used to obtain the samples between 8:00 a.m. and
2:00 p.m. (except the ictal samples, which were acquired
during attacks between 7:00 a.m. and 7:00 p.m.). Plasma
samples were separated (3000 rpm at 4 °C for 15 min)
and stored at − 80 °C until determination of Trp
metabolites by ultra high-performance liquid chroma-
tography–tandem mass spectrometry (UHPLC–MS/
MS). Samples were coded to allow for blind
measurements.
From among the 50 migraineurs, 47 samples were ac-
quired during the interictal phase and 12 samples were
acquired during the ictal phase (all samples derived from
different patients). Self-controlled paired samples were
taken from 10 migraine patients during both periods.
Interictal phase was defined as headache-free period at
least 48 h after the last attack, considering the possibility
of postdrome phase. During headache attacks, patients
were asked not to take their usual painkillers or specific
migraine attack medication until blood samples were
taken. There were no restrictions regarding food and
drink intake. Exclusion criteria for both the EM and
control group included the presence of other type of
headache (e.g. tension type headache) less than 48 h be-
fore sampling or other chronic pain conditions related
to traumatic events or serious systemic disorders such as
cardiovascular and metabolic diseases, immunological,
neurological disorders, as well as clinically diagnosed
psychiatric disorders. Subsequently, using any kind of
chronic medication was also not allowed. We used the
Hamilton’s depression scale before samplings to screen
participants for depression. Detailed headache question-
naires were taken from migraineurs regarding the dur-
ation of disease and attacks, the frequency of attacks, the
subjective feeling of the intensity of pain measured by a
numeric Visual Analogue Scale (VAS), the presence of
allodynia, provocative factors, prodromal- and accom-
panying symptoms, the relationship between hormonal
changes (menstruation cycle, contraceptive drugs) and
migraine attacks and the occurrence of migraine in the
family. Table 1 contains relevant demographic and clin-
ical data.
Quantitative determination of Trp metabolites by UHPLC–
MS/MS – method validation
Recently, we have published a paper [33] on the develop-
ment of a new, robust UHPLC–MS/MS method for sim-
ultaneous quantitative characterization of Trp and 11 of
its metabolites. The method was applied for quantifica-
tion of these metabolites in cerebrospinal fluid and
serum samples of patients with multiple sclerosis and
now for plasma samples of migraineurs. Briefly, plasma
samples were deproteinized with acetone–methanol
mixture containing stable isotope labeled form of 12 me-
tabolites as internal standards. Half of the supernatants
were esterified with n-butanol and then remixed with
the untreated fraction to analyze butylated 3-HK, PICA,
and QUIN in the same chromatographic run with nine
underivatized metabolites. Chromatographic separation
was performed on a pentafluorophenyl column
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(Phenomenex, Torrance, CA, US) using formic acid con-
taining water–methanol gradient solvent system. All
mass spectrometric measurements were conducted using
the Q Exactive™ Plus Hybrid Quadrupole-Orbitrap Mass
Spectrometer (Thermo Fisher Scientific, San Jose, CA,
USA) connected online to an ACQUITY I-Class UPLC™
liquid chromatography system (Waters, Manchester,
UK). As in our recent publication [33], the validation
process was carried out on serum and cerebrospinal
fluid samples, we decided to validate the method for
plasma samples too. For the validation process, the
linearity, limits of detection (LOD) and quantification
(LOQ), precision, accuracy, and recovery were assessed
following the official guidelines.
Statistical analysis
We performed several different analyses to make sure all
clinical parameters were considered. Firstly, all patients
(migraine with aura (MWA) or without aura (MWoA))
were analysed together, forming three groups: healthy
control, interictal and ictal phase patients. In all cases,
the normality and homogeneity of variance were tested;
afterwards, Kruskal-Wallis tests were run. Additionally,
we assessed group differences using two robust probes,
which test the equality of group variances (Welch- and
Brown-Forsythe tests). Thereafter, we divided migrai-
neurs in two subgroups according to the presence of
aura, and compared the interictal data of these sub-
groups to healthy subjects separately. For later analyses,





Age (years) 33.22 ± 9.07 30.50 ± 12.77
Number of patients/samples in different subgroups
according to the different comparisons
All patients, n = 50
Interictal sample, n = 38
Ictal sample, n = 12
n = 34
No regular headache syndromes, chronic diseases and drugs.
All interictal patients, n
= 47
Migraine with aura
samples, n = 11
Migraine without aura
samples, n = 36
All Migraine without
aura patients n = 38
Interictal samples, n = 28
Ictal samples, n = 10
Clinical data of Migraine without aura patients
(ninterictal samples = 36, nictal samples = 10)
Disease Duration (years) 12.50 ± 15.00
Attack frequency (attack/year) 29.50 ± 29.50
Visual analogue scale (VAS) moderate n = 7, severe n = 29
Allodynia No n = 22, Yes n = 14
Menstruation No n = 20, Yes n = 16
Contraceptives No n = 25, Yes n = 11
Prophylactic therapy before the interictal sampling No n = 27, Yes n = 9 (iprazochrome + magnesium orotate n =
4, topiramate n = 4, valproic acid n = 1)
Regular attack therapy eletriptan, sumatriptan > diclophenac > acetylsalicylic acid +
metoclopramide, indometacin, nimesulid, naproxen
Last attack before the interictal cupping (days) 7.00 ± 9.00
Prophylactic therapy before ictal cupping No n = 7, Yes n = 3 (iprazochrome + magnesium orotate n = 1,
topiramate n = 2
Ictal sampling (ICHD3rd symptoms) Beginning of attack
(hours)
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we only used the MWoA group data due to the sample
size and the relevant differences identified in previous
statistical tests. The effect of clinical parameters (disease
duration, attack frequency, VAS, presence of allodynia,
involvement of menstruation cycle, applied therapies
and age) on the metabolic changes was investigated only
in the MWoA subgroup using linear regression models
and two independent samples analyses. Median of data
and value of interquartile range (IQR) were represented
in the figures. Significance level was accepted at p < 0.05.
Furthermore, we opted to confirm our results in a
multivariate setting, since the metabolites in this study
are parts of interconnected pathways and exhibit high
interdependence and cross-correlation. Specifically, we
asked whether participants could be accurately classified
as migraine patient or healthy participant in our sample
based on all measured interictal metabolite levels, and
which metabolites are (most) important in making this
distinction. PLS models are suitable in datasets where
variables exhibit multicollinearity [34], and can be ex-
tended to a LDA model by using the latent variables es-
timated during the PLS analysis, a classification method
widely used in metabolomics and chemometrics [35]. As
the details of the PLS-LDA method are described else-
where [36], we provide a brief delineation in Supplemen-
tary Description 1. Only participants with a complete
metabolite profile were included in the PLS-LDA model
(nhealthy = 30, nmigraine = 37). Age was also included as an
independent variable to account for the possible effect it
has on metabolite levels. The PLS-LDA analysis was
performed in MATLAB R2012 (MathWorks, Inc.)




The LOD, LOQ, retention time, and linearity of the cali-
bration curves with r2 values are shown in Suppl. Table 1
for plasma. For all analytes, r2 exceeded 0.99. In each
case, LODs were less than 9.75 nM. The intra- and
inter-day precision values of the method for plasma
(Suppl. Table 2 and Table 3) lead to the conclusion that
the developed method has reliable precision. The accur-
acy ranged from 85.1 to 114.8% (Suppl. Table 2 and
Table 3), whereas the recoveries of the analytics ranged
between 90.28 and 101.81% for “blank” plasma (Suppl.
Table 4). Our values are in the range recommended by
the official guidelines [ICH, FDA]. Concentrations of 12
metabolites (Trp, KYN, KYNA, ANA, 3-HK, XA, 3-
HANA, PICA, QUINA, 5-HT, 5-HIAA, MELA) of the
KP starting from Trp were determined during this ex-
periment. Levels of 5-HT and MELA were undetectable
in some samples; therefore, their sample sizes for mea-
surements are described separately.
Differences in plasma levels of Trp metabolites between
interictal/ictal periods of migraineurs and healthy
controls
We detected significantly lower plasma concentrations
of Trp metabolites (Trp, KYN, ANA, XA and PICA) in
the interictal phase of migraineurs (n = 38) compared to
the healthy control group (n = 34). MELA showed a
similar tendency but did not reach statistical significance
(ncontrol = 30 vs. ninterictal = 37 vs. nictal = 10). Details are
included in Table 2. A tendency of elevated Trp metab-
olite levels were revealed in the ictal phase of migrai-
neurs (n = 12) compared to the attack free period but
only PICA levels differed significantly (34.86 ± 13.73 vs.
46.04 ± 24.39; p < 0.049) (Fig. 1a). Level of 5-HT showed
opposite alterations between controls (n = 17) and pa-
tients (ninterictal = 25, nictal = 8) compared to other metab-
olites, but the difference was not significant in any of the
cases. The interictal data of 10 migraineurs, whose
plasma samples were collected from both periods, were
excluded from this analysis to avoid statistical problems.
The PLS-LDA model achieved the best classification
results with 3 latent variables extracted in the PLS de-
composition, with a sensitivity of 63.33%, a specificity of
75.68% and an AUC of 0.84 (RMSE = 0.29). Metabolites
which proved most definitive in the classification
(chosen as having a VIP of > 1; see the Supplementary
Description 1 for further details) were similar to those
that showed alterations in the migraine group, namely
Trp, ANA, 3-HK, XA, 3-HANA, PICA, 5-HIAA, MELA
(Fig. 1b).
Differences in plasma levels of Trp metabolites between
migraine with aura/without aura and healthy controls
To see whether Trp metabolism differs in the presence
of aura, we divided the patients into two subgroups:
MWA (n = 11) and MWoA (n = 36). Decreased interictal
plasma concentrations of Trp metabolites were mea-
sured in both subgroups of migraineurs (except of 5-
HT), but significant alterations were detected in the Trp,
KYN, KYNA, ANA, XA, PICA and MELA levels in the
MWoA group compared to healthy controls (n = 34). In
MWA patients, only the expression of PICA was signifi-
cantly lower compared to controls (33.72 ± 17.84 vs.
46.61 ± 25.63; p < 0.038). Details can be seen in the Fig. 2
and Suppl. Table 5.
Differences in plasma levels of Trp metabolites between
groups of interictal/ictal periods of migraine without aura
and healthy controls
According to the results of previous comparisons, only
the data of MWoA patients were analysed further. Sig-
nificantly lower plasma concentrations of Trp metabo-
lites (Trp80%, KYN76%, KYNA81%, ANA73%, PICA77%,
QUINA74%, 5-HIAA80% and MELA79%) were detected in
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the interictal phase of patients (n = 28) compared to
healthy subjects (n = 34, cmetabolites = 100%). During the
ictal period (n = 10) the concentrations of Trp86%,
KYN99%, KYNA94%, ANA109%, PICA99%, QUINA95%, 5-
HIAA93% and MELA100% tended to show higher levels or
in some cases (ANA109%, 3-HK116% and XA101%) the
concentrations were over the control (Fig. 3 and Suppl.
Table 6). Two independent samples comparison showed
that concentrations of ANA (34.45 ± 15.95 vs. 51.18 ±
33.64, p < 0.040), 5-HIAA (36.14 ± 9.26 vs. 41.95 ± 8.83,
p < 0.030) and MELA (0.15 ± 0.07 vs. 0.19 ± 0.08, p <
0.37) increased significantly during the ictal period com-
pared to the attack free phase in MWoA patients.
Associations between altered plasma Trp metabolites in
the interictal periods of migraine without aura patients
and clinical parameters
Altered KYNA concentrations were identified in dif-
ferent subgroups of 36 interictal migraineurs accord-
ing to the clinical parameters: patients were divided
into groups depending on whether their headache was
sensitive to their menstruation cycle (30.87 ± 7.21,
n = 16) or not (36.84 ± 8.84, n = 20; p < 0.014); and the
subjective intensity of their headache, such as moder-
ate (28.84 ± 6.63, n = 7, VAS 5–7) or severe (35.72 ±
8.63, n = 29, VAS 8–10; p < 0.017). Mild linear
relationships were realised between the attack fre-
quency and concentration changes of XA (p < 0.047,
R = − 0.379) and MELA (p < 0.024, R = − 0.427).
Significant correlations were found between the age
of healthy controls and their plasma XA (p < 0.024
R = − 0.386) and MELA (p < 0.035, R = − 0.387) levels,
but this was not observable in migraineurs (interictal
XA and age: p < 0.077, R = − 0.339) (Fig. 4). The other
examined clinical features did not show correlation
with the plasma concentrations of metabolites.
Associations between altered plasma Trp metabolites in
the ictal periods of all migraine patients and their clinical
parameters
We found positive correlation between the ictal
concentrations of PICA and the last attack before the
ictal sampling (p < 0.031, R = 0.620), as well as be-
tween the ictal concentrations of 3-HK and the begin-
ning of attack before ictal sampling (p < 0.0004, R =
0.853). However, only 12 samples could be included
in this analysis, which highly limits the results and
conclusions (Fig. 5).
Discussion
In this study, we present a detailed analysis of Trp
metabolism including kynurenine, 5-HT and MELA
pathways in the peripheral plasma of episodic migrai-
neurs, with special attention to alterations in the
interictal/ictal periods and clinical associations. The
importance of Trp, 5-HT and MELA has already been
identified in migraine [8, 9, 11], however the KP has
received little attention in human studies. The KP is
the main branch (95%) of Trp catabolism and its sev-
eral metabolites can influence different pain-related
Table 2 Plasma concentrations of Trp metabolites in healthy controls and migraineurs in both interictal and ictal periods
Metab.
(nM)
Groups: Median ± IQR p-values
between
groups
0. Healthy Control 1. Interictal Migraine 2. Ictal Migraine
Trp 53,203.65 ± 14,599.34 45,657.54 ± 4711.21 45,210.69 ± 11,292.49 0–1: 0.008
KYN 2505.77 ± 902.53 2119.41 ± 648.54 2418.99 ± 819.22 0–1: 0.003
KYNA 39.59 ± 15.32 33.56 ± 15.64 36.01 ± 10.57 0–1: 0.061
ANA 47.12 ± 27.79 35.23 ± 18.88 44.39 ± 28.61 0–1: 0.017
3-HK 47.29 ± 27.89 44.79 ± 18.73 48.41 ± 34.54 0–1: 0.511
XA 17.42 ± 13.46 11.39 ± 5.31 17.61 ± 14.66 0–1: 0.02
3-HANA 47.78 ± 24.59 44.85 ± 23.61 42.40 ± 21.24 0–1: 0.733
PICA 46.61 ± 25.63 34.86 ± 13.73 46.04 ± 24.39 0–1: 0.005
1–2: 0.049
QUINA 252.92 ± 169.69 190.86 ± 97.12 239.66 ± 178.05 0–1: 0.096
5-HT 468.11 ± 710.24 772.24 ± 493.89 491.23 ± 509.87 0–1: 0.243
5-HIAA 45.31 ± 20.46 37.46 ± 11.19 42.67 ± 11.10 0–1: 0.063
MELA 0.19 ± 0.11 0.16 ± 0.09 0.21 ± 0.10 0–1: 0.053
All p-values were added in the table between control and interictal group of migraine patients. Significant difference between phases of migraine was revealed
only in case of PICA
IQR: interquartile range, Metab.: metabolites, Trp: Tryptophan, KYN: L-kynurenine, KYNA: Kynurenic acid, ANA: Anthranilic acid, 3-HK: 3-hydroxikynurenine, XA:
Xanthurenic acid, 3-HANA: 3-hydroxi-anthranilic acid, PICA: Picolinic acid, QUINA: Quinolinic acid, 5-HT: 5-hydroxytryptamine, 5-HIAA: 5-hydroxi-indoleaceticacid,
MELA: Melatonin
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Fig. 1 (See legend on next page.)
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mechanisms, including glutamate-mediated neuro-
transmission, immunological or antioxidant processes.
Simultaneous investigation of the different routes of
Trp metabolism can get us closer to the metabolomic
alterations characteristic of migraine.
Our results show that the entire metabolic route is sig-
nificantly depressed during the interictal period in
migraineurs, but a tendency of elevated metabolite levels
was found during the ictal period. Our hypothesis is that
decreased Trp metabolism can enhance the susceptibility
of patients to the formation of headache attacks. Since
all metabolites are closely related to each other, focusing
on the provoking effect of individual metabolites might
be an oversimplification. More likely, altered metabolite
levels paired with other known/unknown trigger mecha-
nisms might have an additive effect that can culminate
in an attack when the threshold has been exceeded [37].
The headache attack might be a response to cerebral
energy deficit or oxidative stress, which can manifest in
impairment in different structures of the brain or
striated muscles, elevated lactate levels of the occipital
cortex in patients with aura, mitochondrial enzyme dys-
functions and abnormalities in glucose/lipid metabolism
[38]. These alterations possibly derive from several per-
ipheral disturbances, which might pose initiating factors
for neurological disorders.
For instance, if the Trp and its metabolites have lower
concentration in the CNS of migraineurs, the brain is
supposedly able to take up Trp from the periphery
through large neutral amino acid transporters [39, 40] in
order to synthesise the required molecules. This mech-
anism can protect the brain from damage (also known
as counterbalancing excitotoxicity), maintain the central
homeostasis, but generate a totally imbalanced Trp path-
way manifesting in low peripheral metabolite levels. The
extremely reduced metabolite concentrations (as energy
deficit) can easily lead to elevated intracellular Ca2+
levels through several complex mechanisms, which can
finally initiate an attack through enhanced hypersensiti-
zation in the CNS [41].
The centrally accumulated metabolites can release into
the blood in order to redistribute the molecules in the
periphery. This might be a comprehensive regulating
feedback mechanism, the aim of which is to reconstitute
the control level protecting the organism without the ex-
cessive exhaustion (Fig. 6). However, there is a complex
relationship between peripheral and central Trp path-
ways, so it is unknown whether plasma concentrations
assessed in our study reflect brain concentrations of me-
tabolites. While changes in the plasma can occur within
a larger range influenced by certain drugs or diet, me-
tabolite levels in the brain are more constant. It is pre-
sumed that decreased levels of metabolites in the
peripheral plasma are attributable to 1) less Trp intake
or 2) that the brain can reserve the needed metabolites
for itself from the blood. The latter depends on the 1)
permeability of blood-brain barrier (BBB), the integrity
of which is subject to debate in migraine [42] and 2) the
ability of certain molecules to traverse the BBB; in this
case the Trp, KYN and 3-HK are considered as well
penetrating, actively transported metabolites, while other
knyurenine agents can pass via passive diffusion [39].
The function of these metabolites is complicated and
hard to pin down due to their widespread involvement
in different mechanisms. Most of the investigated mole-
cules are considered protective factors (Trp, KYN,
KYNA, ANA, PICA, MELA) and their elevated levels in
the periphery might be a consequence of the migraine
attack, possibly aimed to restore the balance of energy
homeostasis and protect the organism against harmful
effects. However, there are molecules with more ambigu-
ous roles (5-HIAA or 3-HK, 3-HANA and QUINA), the
increased expression of which might contribute to the
formation or aggravation of headache attacks.
Both migraine and the KP were extensively investi-
gated in association with exercise and dietary habits,
subsequently energy and metabolic homeostasis and im-
mune system [38, 43, 44]. Although their relationship is
not clear as of today, long-lasting peripheral changes
and imbalance in Trp metabolism can putatively partici-
pate in the development of migraine.
Role of Trp, 5-HT, 5-HIAA and MELA in migraine
In humans, dietary Trp is utilised either for the synthesis
of proteins, 5-HT and MELA or oxidised via the KP at
the periphery. In this study, the individual dietary habits
(See figure on previous page.)
Fig. 1 a. Plasma concentrations of Trp, KYN, ANA, XA, PICA and MELA in controls and migraineurs in both interictal/ictal periods (median,
interquartile range, minimum, maximum values and outliers were presented in this figure). Sample sizes in groups: healthy control (n = 34),
interictal phase of migraineurs (n = 38), ictal phase of migraineurs (n = 12). Sample sizes in case of MELA: healthy control (n = 30), interictal phase
of migraineurs (n = 37), ictal phase of migraineurs (n = 10). Significance levels: * p < 0.05, ** p < 0.01. Trp: Tryptophan, KYN: L-kynurenine, ANA:
Anthranilic acid, XA: Xanthurenic acid, PICA: Picolinic acid, MELA: Melatonin. b. Results of the partial least squares – linear discriminant analysis
(PLS-LDA). Left: The bar plot depicts variable importance projection (VIP) scores of variables used in the PLS decomposition. Right: 3D-projection
plots of migraine and healthy metabolite profiles in the PLS latent variable space. The classification hyperplane was obtained using linear
discriminant analysis. Trp: Tryptophan, KYN: L-kynurenine, KYNA: Kynurenic acid, ANA: Anthranilic acid, 3-HK: 3-hydroxykynurenine, XA: Xanthurenic
acid, 3-HANA: 3-hydroxy-anthranilic acid, PICA: Picolinic acid, QUINA: Quinolinic acid, 5-HIAA: 5-hydroxy-indoleaceticacid, MELA: Melatonin, PLS-
LDA: partial least squares–linear discriminant analysis
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of our participants were not assessed in detail, but none
of them followed extreme diet regimes. The cause of de-
creased Trp level during attack-free periods is unknown,
but evidence exists for associations between depleted
Trp condition/less Trp intake with more frequent head-
ache, glare/light-induced pain and vegetative symptoms
Fig. 2 Differences in plasma levels of Trp, KYN, KYNA, ANA, XA, PICA, 5-HIAA and MELA between patients with aura (MWA) and without aura
(MWoA) (median, interquartile range, minimum, maximum values and outliers were presented in this figure). Sample sizes in groups: healthy
control (n = 34), interictal phase of MWA (n = 11), interictal phase of MWoA (n = 36). Sample sizes in case of MELA: healthy control (n = 30),
interictal phase of MWA (n = 9), interictal phase of MWoA (n = 28). Significance levels: * p < 0.05, ** p < 0.01. Trp: Tryptophan, KYN: L-kynurenine,
KYNA: Kynurenic acid, ANA: Anthranilic acid, XA: Xanthurenic acid, PICA: Picolinic acid, 5-HIAA: 5-hydroxy-indoleaceticacid, MELA: Melatonin
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Fig. 3 Differences in plasma levels of Trp, KYN, KYNA, ANA, PICA, QUINA, 5-HIAA and MELA between groups of interictal/ictal phases of migraine
without aura patients and healthy subjects (median, interquartile range, minimum, maximum values and outliers were presented in this figure).
Sample sizes in groups: healthy control (n = 34), interictal phase of MWoA (n = 28), ictal phase of MWoA (n = 10). Sample sizes in case of MELA:
healthy control (n = 30), interictal phase of MWoA (n = 22), ictal phase of MWoA (n = 9). Significance levels: * p < 0.05, ** p < 0.01, *** p < 0.001.
Trp: Tryptophan, KYN: L-kynurenine, KYNA: Kynurenic acid, ANA: Anthranilic acid, PICA: Picolinic acid, QUINA: Quinolinic acid, 5-HIAA: 5-hydroxy-
indoleaceticacid, MELA: Melatonin
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[10]. Moreover, approximately 1 g per day Trp consump-
tion seems to reduce the risk of migraine by half [11],
therefore exogenous Trp intake should be considered in
following studies. Consequently, the decreased Trp con-
centration can result in the diminished synthesis of con-
secutive metabolites: e.g. 5-HT, the reduction of which
can aggravate phonophobia [10].
Exact correlation has not been found between Trp hy-
droxylase gene polymorphisms and migraine in genetic
studies yet [45], but several studies provide evidence that
fluctuating levels of 5-HT both in the periphery and
brain take part in the initiation of headache attacks [6, 8,
46–48]. Our results concerning the higher interictal
plasma 5-HT level may also explain the decreased Trp
level in the attack-free phase and it can serve as protect-
ive factor, if we agree with theories that 1) the 5-HT
level in platelets can suddenly fall down during attack
[49] and 2) the intravenously administered 5-HT is able
to abolish both the spontaneous and induced migraine
attacks [50]. However, these 5-HT data were not so
homogenous and significant alterations were not de-
tected between groups, therefore detailed and exact con-
clusions could not be drawn.
However, 5-HIAA seems to be an active metabolite,
because 1) its decreased level in the CSF has previously
been demonstrated in patients with depressive disorders
and idiopathic pain syndromes [51] and it is also used as
indicator of serotonergic activity [52], 2) its exogenous
Fig. 4 Associations between metabolic changes and clinical features of MWoA patients in the interictal period, and age of healthy controls
(median, interquartile range, minimum and maximum values were presented in the figures of KYNA). Sample sizes in groups: interictal phase of
migraineurs without aura (n = 36); Sample size in case of MELA: healthy control (n = 30), interictal phase of migraineurs without aura (n = 28).
KYNA: Kynurenic acid, XA: Xanthurenic acid, MELA: Melatonin
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administration resulted in potentiated thermal hyper-
algesia and 3) depressed 5-HIAA content was measured
in nerve tissues, if 5-HT synthesis inhibitor was applied
as pretreatment in a Complete Freund’s Adjuvant
(CFA)-induced peripheral inflammation model [53]. The
interictally decreased, but ictally increased 5-HIAA
plasma levels observed in our study are not fully in line
with previously detected alterations in migraineurs [46],
which shows that the exact role of 5-HIAA has not been
clarified yet. Higher 5-HIAA levels seem to be a trigger-
ing or aggravating factor of headache, which may origin-
ate from interictally increased 5-HT levels (paired with
an unknown trigger the metabolism of 5-HT can shift
toward the 5-HIAA resulted in the formation of attack,
while the concentration of plasma 5-HT decrease).
5-HT is converted indirectly to MELA, which is a po-
tent antioxidant and takes part in the regulation of circa-
dian rhythm and depression. In migraineurs, decreased
MELA concentrations were found in nocturnal plasma
samples [54], which showed an association with hormo-
nal changes [7]. The importance of MELA in migraine
was realised when patients exhibited a normalized
biological clock, diminished headache frequency and re-
duced headache intensity following MELA administra-
tion. It is presumed that the migraine attack might be a
response to the irregularity of pineal cycles [9, 55].
This concept fits our results, wherein the interictally
decreased MELA concentration might be a trigger of
subsequent attacks through the absence of its protective
effect. The accumulated triggering events can evoke
headache attacks, which are accompanied by increasing
MELA concentration in the periphery in order to reach
the normal level and eliminate pain through a positive
feedback mechanism. However, more frequent recurrent
attacks come with lower interictal MELA levels (mild
negative association) according to our results, which
might be a sign of impaired re-balancing of MELA levels
in migraine. Additionally, age-related lower MELA con-
centrations were found in our controls suggesting that
circadian disturbances are more frequent in the older
population due to increased susceptibility for impaired
redox homeostasis, suppressed MELA levels and subse-
quently chronodisruption [56]. Presumably, this associ-
ation can stay in hidden in migraineurs due to their
other specific alterations.
Role of the KP in migraine
The relevance of kynurenine metabolites in migraine is
only partially elucidated but the antiglutamatergic [4],
anti-inflammatory [57] antioxidant [58] and antinocicep-
tive features of KYNA are established. It acts on the per-
ipheral and central arms of the TS, therefore KYNA or
its derivatives can diminish nociception and hyperalgesia
[59, 60], block the cellular activity of migraine generators
[61] and inhibit sensitization and neuro-inflammation
[29, 62] in different preclinical models. Although the
peripheral modulating action of KYNA on sensory and
trigeminal nerves is very important in alleviating the
mechanisms of migraine [63], its central effect is not so
direct because of its poor ability to cross the BBB. KYN
penetrates the brain more efficiently, which can fuel the
KP giving a basis for conversion of downstream metabo-
lites (e.g. KYNA) in the CNS [27, 28].
Fig. 5 Associations between altered concentrations of PICA and 3-HK and ictal characteristics of all migraine patients (n = 12). PICA: Picolinic acid,
3-HK: 3-hydroxykynurenine
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There is evidence that endogenous KYNA synthesis in
the dura may contribute to the modulation of NMDA
receptor function [23]; additionally, lower KYNA con-
centrations may be accompanied by the overactivation
of NMDA receptors [31]. Considering this, decreased
KYNA levels observed in the headache free period of
our patients can evoke attacks through glutamate excess.
Several studies confirm that glutamate is involved in the
processes of migraine [1], although there are mixed re-
sults concerning the glutamate level during interictal/
ictal periods [3, 64]. The ictally elevated glutamate con-
centration in the CSF may reflect persistent neuronal hy-
perexcitability, while glutamate receptor antagonists are
able to mitigate both the headache [65] and aura phase
[66]. The essential role of glutamate in the development
of CSD is supported by multiple studies [67, 68], more-
over the elevated KYNA levels observed in the ipsilateral
hemispheres of rat after triggered CSD [69] call attention
to a protective feedback mechanism. This defensive
phenomenon might underlie higher interictal KYNA
levels identified in migraine patients whose headache
was not related to menstruation cycle compared to pa-
tients whose migraine was sensitive to hormonal
changes. Both migraine attacks and the KP are highly in-
fluenced by the female hormone system. In a preclinical
study elevated CSD frequency was observed in female
rats, when estrogen levels were higher [70], but treat-
ment with KYN significantly decreased the frequency of
CSD due to the increased cortical levels of KYNA. Fe-
males have a higher intrinsic capacity to synthesize
KYNA in baseline conditions than males due to the dif-
ference between sex hormones on the synthesizing en-
zymes involved in Trp metabolism [30]. This suggests
that the expression of KYNA is exposed to the impact of
hormones in menstruation dependent migraineurs
resulting in significant decreased interictal KYNA con-
centration. If the hormonal effects are not so intense,
the level of KYNA might stay in a higher, protective
Fig. 6 Scheme of altered Trp catabolism and potential mechanisms during interictal/ictal periods in episodic migraineurs. LNAAT: large neutral
amino acid transporter, Trp: Tryptophan, 5-HT: 5-hydroxytryptamine, 5-HIAA: 5-hydroxy-indoleaceticacid, MELA: Melatonin, KYN: L-kynurenine,
KYNA: Kynurenic acid, ANA: Anthranilic acid, 3-HK: 3-hydroxykynurenine, XA: Xanthurenic acid, 3-HANA: 3-hydroxy-anthranilic acid, PICA: Picolinic
acid, QUINA: Quinolinic acid. Continuous arrow: direct step in the pathway, Dashed arrow: indirect step in the pathway
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range in the attack free phase. Similarly, in another
study, significantly lower MELA levels were detected
throughout the ovarian cycle in menstruation-related
MWoA patients than in controls [7, 71].
The higher interictal KYNA level in patients with
higher headache intensity during the attack may repre-
sent a compensatory event aimed at reinforcing en-
dogenous analgesic mechanisms. During severe
headache, the organism generates a large amount of pro-
tective compounds in order to eliminate the pain. How-
ever, further investigation is required to clarify the
relationship between KYNA levels and VAS due to cer-
tain limitations (few number of patients, subjectivity of
VAS). The endogenous compensatory effect of elevated
KYNA level was described in an animal experiment,
where both glutamate and KYNA levels in the TNC in-
creased significantly during the early state of peripheral
inflammation induced by CFA. Glutamate excess can ex-
acerbate pain, while KYNA is able to inhibit glutamate
excitotoxicity via NMDA receptor antagonism. Altered
glutamate metabolism in migraine is undisputable and
KYNA can be protective against trigeminal hyperactivity,
but medications targeting the glutamatergic pathway
have limited time interval [26].
Beside glutamatergic processes, there are other targets,
mechanisms and metabolites of the KP [31, 32], which
can influence the development of headache disorders.
Oxidative stress and excitotoxicity [38], microstructural
lesions [72, 73] and immunological alterations [74] are
mainly interrelated and both are regulated by
kynurenines.
Oxidative stress-excitotoxicity-neurodegeneration
In neurodegenerative disorders, KYN, PICA and ANA
serve as protective agents through their ability to block
cholinergic toxicity, neuronal loss and glial proliferation.
Although both inhibitory and excitatory properties of
PICA have been reported [75, 76], it is mainly consid-
ered as an endogenous neuroprotective compound
within the brain [77, 78] due to its ability to chelate
metal ions and effectively inhibit neurotoxicity at the
NMDA receptor [79]. In our study the level of PICA
showed significant reduction in MWA patients com-
pared to healthy controls. Investigation of MWA and
MWoA in separate groups is justified by functional and
structural differences between the two subtypes [73, 80],
and the interactions between 5-HT pathway and pres-
ence of aura/ovarian hormones both in CSD model [70]
and in MWA patients [81], but we did not find signifi-
cant differences. The positive association we found be-
tween the ictal level of PICA and the number of days
since the last migraine attack points to protective fea-
tures of PICA and suggests that in patients who recently
had a migraine attack, systemic PICA expression is
exhausted, bringing about only a slight PICA increase in
the plasma during the analysed attack. Presumably, ele-
vated PICA expression occurred during the last attack
but fell again suddenly due to triggers contributing to
the next attack. However, this interpretation has limita-
tions in this study (number of samples, lack of individual
consecutive inter-ictal periods).
Lower KYNA, PICA and/or XA concentrations were
measured in patients with depressive episodes [82, 83]
and in different stages of schizophrenia [84], which con-
firm the importance of accurate and detailed differential
diagnosis, especially in case of psychiatric involvement.
Not only disease-, but also age-specific correlations were
detected between the activity of cerebral KP and neuro-
genesis/excitotoxicity [85], where XA was prominent
[86]. Similarly, we found negative correlation between
XA levels and age in our control population. The en-
dogenous protective features of XA can explain this as-
sociation: it has important function in synaptic signalling
transports, effective reduction of 3-HK neurotoxicity by
transamination [87], moreover it has sedative and anal-
gesic properties in higher doses [88]. Our data showed a
weak negative correlation between the interictal concen-
trations of XA and attack frequency suggesting the ab-
sence of protective function: during recurrent attacks,
the peripheral concentration of XA cannot return to the
control level, causing persistent low levels in the blood.
Generally, 3-HK, 3-HANA and QUINA are cate-
gorised as pro-oxidant and proinflammatory molecules,
elevated levels of which can generate reactive oxygen
species (ROS) and neuronal toxicity, resulting in neur-
onal death [89] via NMDA agonism, endogenous glu-
tamate release/uptake inhibition [90], enhanced lipid
peroxidation [91] and altered BBB integrity [92]. Al-
though these alterations are mainly characteristic for
neurodegenerative disorders [93, 94], microstructural al-
terations observed in the white matter of the migraine
brain (“maladaptive plasticity”) can be considered as the
prelude of degeneration.
In neurodegenerative disorders, 3-HK and QUINA
tend to function as harmful substances [33, 95, 96], but
there are controversial results concerning their toxicity,
which might explain the depressed Trp metabolism ob-
served in our study. 3-HK and 3-HANA can behave as
prooxidant and antioxidant molecules as well [97, 98]. 3-
HANA and QUINA have the ability to form coordin-
ation complexes with iron or copper [99], thereby they
are able to prevent cell damage caused by ROS [100]
and maintain the redox homeodynamic equilibrium
[101]. 3-HANA has anti-inflammatory and immune/neu-
roprotective effects [102], while QUINA can attenuate
CSD in the rat cortex by means of NMDA
desensitization [103]. 3-HK has dual redox modulatory
activity depending on its concentration range. Its
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protective action is related to the stimulation of glutathi-
one- and superoxide systems [104].
In our study, ictal levels of 3-HK showed positive cor-
relation with the elapsed hours since the beginning of at-
tack, which suggests a compensatory mechanism, if the
function of 3-HK is considered as more protective than
neurotoxic. The level of 3-HK is low during the begin-
ning of the attack, but it begins to elevate afterwards in
order to restore metabolic balance. Otherwise, if 3-HK
has toxic effects, it can contribute to the prolongation of
headache. This is in line with findings of reduced Trp,
XA 3-HANA and QUINA levels in connection with neu-
rodegeneration [101], which show that kynurenines have
relatively complex milieu-dependent effects. It is not
clear how alterations of KP vary between different
neurological conditions.
Neuro-immunological relationship
The indoleamine 2,3-dioxygenase (IDO), as a rate-
limiting enzyme of the KP, has a crucial role in main-
taining the neuro-immunological homeostasis [105],
which means it is related to the development of migraine
[106]. Enhanced activity of IDO and pro-inflammatory
changes controlled by several immunological factors
were observed in migraineurs [107], possibly reflecting a
shift of Trp toward the KP, which results in lower
plasma 5-HT availability in the interictal period of pa-
tients. This theory was supported by the finding that ad-
ministration of niacin improved migraine symptoms
[108] due to the shift of Trp metabolism toward 5-HT
synthesis. Our data may suggest that the interictally
higher 5-HT level can drain the Trp resource; thereby
the increased 5-HT concentration can maintain the
interictal, “resting” state (without symptoms – see as
niacin effect). Meanwhile, the plasma Trp resource de-
creases further because of the transport of Trp to the
brain in order to maintain the central homeostasis,
resulting in an attenuated Trp catabolism toward the
KP. Eventually, the peripheral Trp concentration reaches
an extreme low level, when neither the plasma 5-HT nor
the brain Trp level is high enough to prevent the head-
ache attack. Apart from Trp, ANA has a protective, im-
munological effect, exhibiting iron chelating, ROS
scavenging and antioxidant features. An ANA derivative
compound was able to suppress the activation of mono-
cytes and interferon-gamma induced microglial nitric
oxide synthase activity [109]. In our study, significantly
decreased concentrations of ANA were observed during
the attack free period in MWoA patients (73.11%) com-
pared to healthy controls (100%), which elevated re-
markably during the ictal period (108.62%). Low ANA
levels might be a contributing factor to elicit the next at-
tack, while its high expression during the ictal period
might be a positive feedback response. This elevation is
more moderate than what Curto and co-workers ob-
served in the serum of chronic migraineurs [31], but it
can prove the importance of ANA.
KP and its relation with other systems
Activation of the KP might also be associated with
migraine-related peptidergic systems. In our previous
study we showed that concentrations of pituitary adenyl-
ate cyclase-activating polypeptide 1–38 (PACAP1–38)
and calcitonin gene-related peptide (CGRP) decreased in
the peripheral plasma during the interictal period in
migraineurs, while their levels increased during attacks
[110]. An association between the KP and PACAP sys-
tem was revealed in a rat model of activated TS: pre-
treatment with KYNA and its derivative were able to di-
minish the expression of PACAP1–38 both at proteomic
and transcriptomic levels in the peripheral plasma and
brain tissues [5]. It is hypothesised that decreasing ex-
pression of TRP metabolites can generate an increase in
not only glutamate levels but also PACAP1–38 and
CGRP concentrations, which can contribute to the for-
mation of migraine attacks. However, this needs further
investigations.
Conclusion
Since migraine is a multifactorial disease, targeting com-
plex pathways could be advantageous to improve thera-
peutic strategies. It seems that chronically low peripheral
levels of TRP metabolites can initiate molecular distur-
bances underlying migraine pathomechanism, which
may participate in triggering events (e.g. glutamate ex-
cess, oxidative stress, altered immune functions and neu-
roinflammation) that can induce hyperexcitability and
culminate in headache attacks. The attack itself can be
considered as a response to the unbalanced peripheral
energy metabolism and the consequent increase in levels
of kynurenine, 5-HT and MELA metabolites may serve
as protective factor. Our systematic and detailed analysis
revealed associations between Trp metabolism and clin-
ical features of migraine, which may lead to new thera-
peutic options in the future.
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